Se-Hoon Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6806906/publications.pdf

Version: 2024-02-01

152 papers	9,005 citations	44444 50 h-index	54771 88 g-index
153 all docs	153 docs citations	153 times ranked	13852 citing authors

#	Article	IF	Citations
1	Gene essentiality for tumour growth influences neoantigenâ€directed immunoediting. Clinical and Translational Medicine, 2022, 12, e714.	1.7	0
2	Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. Journal of Neuro-Oncology, 2022, 156, 541.	1.4	1
3	Artificial Intelligenceâ€“Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1916-1928.	0.8	94
4	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. Cancer Immunology, Immunotherapy, 2021, 70, 1605-1617.	2.0	8
5	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. Journal of Korean Neurosurgical Society, 2021, 64, 271-281.	0.5	8
6	Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell, 2021, 184, 2487-2502.e13.	13.5	60
7	Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. EPMA Journal, 2021, 12, 629-645.	3.3	0
8	Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach. Cancers, 2021, 13, 6050.	1.7	3
9	Junction Location Identifier (JuLI). Journal of Molecular Diagnostics, 2020, 22, 304-318.	1.2	6
10	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respiratory Medicine, 2020, 161, 105853.	1.3	23
11	Benefit of Targeted DNA Sequencing in Advanced Nonâ€“Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Clinical Lung Cancer, 2020, 21, e182-e190.	1.1	5
12	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 2020, 38, 4138-4148.	0.8	614
13	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
14	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. Scientific Reports, 2020, 10, 13231.	1.6	11
15	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. Journal of Thoracic Oncology, 2020, 15, 1758-1766.	0.5	60
16	Regulatory (FoxP3+) T cells and TGF-Î² predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports, 2020, 10, 18994.	1.6	52
17	MDSC subtypes and CD39 expression on CD8⁺ T cells predict the efficacy of antiâ€PDâ€1 immunotherapy in patients with advanced NSCLC. European Journal of Immunology, 2020, 50, 1810-1819.	1.6	57
18	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. PLoS Medicine, 2020, 17, e1003091.	3.9	9

#	Article	IF	Citations
19	Genomic landscape of acquired resistance to thirdâ€generation EGFR tyrosine kinase inhibitors in EGFR T790Mâ€mutant nonâ€“small cell lung cancer. Cancer, 2020, 126, 2704-2712.	2.0	26
20	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. Nature Communications, 2020, 11, 951.	5.8	34
21	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 446-454.	3.3	75
22	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nature Communications, 2019, 10, 4278.	5.8	263
23	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 193-202.	0.5	104
24	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. Lung Cancer, 2019, 134, 7-15.	0.9	38
25	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncologist, 2019, 24, 751-e231.	1.9	21
26	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. International Journal of Cancer, 2019, 145, 2433-2439.	2.3	26
27	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 408-412.	1.3	15
28	Integrin Î²3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC. Clinical Cancer Research, 2018, 24, 4162-4174.	3.2	13
29	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. Lung Cancer, 2018, 122, 160-164.	0.9	10
30	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE, 2018, 13, e0189766.	1.1	46
31	Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC. Lancet Respiratory Medicine,the, 2017, 5, e10.	5.2	0
32	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nature Communications, 2017, 8, 1377.	5.8	137
33	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Cancer Research and Treatment, 2017, 49, 193-203.	1.3	26
34	Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. Journal of Korean Medical Science, 2017, 32, 415.	1.1	8
35	Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALKâ€rearranged nonâ€small cell lung cancer. Journal of Pathology, 2017, 243, 307-319.	2.1	63
36	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. Korean Journal of Internal Medicine, 2016, 31, 570-578.	0.7	38

#	Article	IF	Citations
37	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. BMC Urology, 2016, 16, 46.	0.6	14
38	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. Head and Neck, 2016, 38, 277-284.	0.9	14
39	Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Nonâ€“Small-Cell Lung Cancer with Activating EGFR Mutation. Journal of Thoracic Oncology, 2015, 10, 1189-1194.	0.5	26
40	<scp>IDH2</scp> mutation in gliomas including novel mutation. Neuropathology, 2015, 35, 236-244.	0.7	19
41	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. Cancer Research and Treatment, 2015, 47, 555-563.	1.3	49
42	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. PLoS ONE, 2015, 10, e0133371.	1.1	7
43	Mechanisms of Acquired Resistance to AZD9291. Journal of Thoracic Oncology, 2015, 10, 1736-1744.	0.5	202
44	Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy: Differentiation of True Progression from Pseudoprogression with Quantitative Dynamic Contrast-enhanced MR Imaging. Radiology, 2015, 274, 830-840.	3.6	102
45	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. Oncologist, 2015, 20, 1119-1120.	1.9	20
46	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean Journal of Internal Medicine, 2015, 30, 891-898.	0.7	10
47	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 182-188.	1.3	3
48	Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide in Glioblastoma Patients: Application of Dynamic Susceptibility Contrast Perfusion and Diffusion-Weighted Imaging. PLoS ONE, 2014, 9, e113587.	1.1	15
49	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. Journal of Korean Medical Science, 2014, 29, 1094.	1.1	22
50	Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea. Journal of Korean Medical Science, 2014, 29, 980.	1.1	67
51	Sunitinib in metastatic renal cell carcinoma: An ethnic <scp>A</scp>sian subpopulation analysis for safety and efficacy. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 237-245.	0.7	40
52	Expression level ofhTERTis regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget, 2014, 5, 3399-3407.	0.8	50
53	Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean Journal of Internal Medicine, 2014, 29, 40.	0.7	31
54	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2014, 46, 323-330.	1.3	21

#	Article	IF	Citations
55	Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging. Journal of Neuro-Oncology, 2013, 112, 427-435.	1.4	18
56	The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2013, 112, 277-283.	1.4	21
57	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer, 2013, 119, 1195-1202.	2.0	136
58	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgical Oncology, 2013, 20, 2242-2249.	0.7	12
59	Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer. Journal of Molecular Diagnostics, 2013, 15, 51-61.	1.2	63
60	Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MSâ€MLPA in patients with glioblastoma multiforme. Journal of Magnetic Resonance Imaging, 2013, 37, 351-358.	1.9	42
61	Tumor Burden is Predictive of Survival in Patients With Nonâ€“Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. Clinical Lung Cancer, 2013, 14, 383-389.	1.1	63
62	Clinicopathologic Analysis of ROS1-Rearranged Nonâ€“Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm. Journal of Thoracic Oncology, 2013, 8, 1445-1450.	0.5	65
63	Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-b-Value Diffusion-weighted Imaging. Radiology, 2013, 269, 831-840.	3.6	147
64	Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1069-1074.	0.5	110
65	Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 415-422.	0.5	147
66	Application of Cancer Genomics to Solve Unmet Clinical Needs. Genomics and Informatics, 2013, 11, 174.	0.4	9
67	Primary Intracranial Germ Cell Tumor Originating From Septum Pellucidum That Mimics Central Neurocytoma. Journal of Clinical Oncology, 2012, 30, e274-e277.	0.8	10
68	Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	25
69	The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use. Japanese Journal of Clinical Oncology, 2012, 42, 1020-1027.	0.6	8
70	Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinomaâ€. Japanese Journal of Clinical Oncology, 2012, 42, 836-844.	0.6	28
71	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, e147-e150.	0.8	47
72	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14476-14481.	3.3	246

#	Article	IF	Citations
73	Comparison of Treatment Outcomes Between Involved-field and Elective Nodal Irradiation in Limited-stage Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 948-954.	0.6	12
74	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer, 2012, 77, 288-292.	0.9	115
75	The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Research, 2012, 22, 2109-2119.	2.4	524
76	Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. Translational Oncology, 2012, 5, 430-436.	1.7	51
77	The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. Translational Oncology, 2012, 5, 393-IN19.	1.7	43
78	Diffusion-weighted MR Imaging for the Differentiation of True Progression from Pseudoprogression Following Concomitant Radiotherapy with Temozolomide in Patients with Newly Diagnosed High-grade Gliomas. Academic Radiology, 2012, 19, 1353-1361.	1.3	96
79	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer, 2012, 48, 324-332.	1.3	84
80	Role of Chemotherapy on Brain Metastasis. Progress in Neurological Surgery, 2012, 25, 110-114.	1.3	9
81	EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer, 2012, 77, 433-437.	0.9	25
82	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer, 2012, 77, 460-463.	0.9	82
83	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer, 2012, 77, 572-577.	0.9	66
84	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data. Journal of Breast Cancer, 2012, 15, 427.	0.8	15
85	Comparative analyses of overall survival in patients with anaplastic lymphoma kinaseâ€positive and matched wildâ€type advanced nonsmall cell lung cancer. Cancer, 2012, 118, 3579-3586.	2.0	49
86	Influence of chemotherapy on nitric oxide synthase, indoleâ€amineâ€2,3â€dioxygenase and CD124 expression in granulocytes and monocytes of nonâ€small cell lung cancer. Cancer Science, 2012, 103, 155-160.	1.7	20
87	Phase II trial of continuous onceâ€daily dosing of sunitinib as firstâ€line treatment in patients with metastatic renal cell carcinoma. Cancer, 2012, 118, 1252-1259.	2.0	84
88	CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumor Biology, 2012, 33, 121-129.	0.8	68
89	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. Journal of Neuro-Oncology, 2012, 106, 303-313.	1.4	64
90	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Supportive Care in Cancer, 2012, 20, 395-403.	1.0	28

#	Article	IF	Citations
91	Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer. Cancer Research and Treatment, 2012, 44, 227-234.	1.3	6
92	Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients. Cancer Research and Treatment, 2012, 44, 242-250.	1.3	17
93	The Role of Chemotherapy in Anaplastic Astrocytoma Patients. Journal of Korean Neurosurgical Society, 2012, 51, 199.	0.5	0
94	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Research, 2011, 13, R22.	2.2	187
95	A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer, 2011, 71, 65-69.	0.9	38
96	Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1474-1480.	0.5	148
97	Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors. Journal of Thoracic Oncology, 2011, 6, 905-912.	0.5	66
98	Clinical significance of tumorâ€infiltrating FOXP3+ T cells in patients with ocular adnexal mucosaâ€associated lymphoid tissue lymphoma. Cancer Science, 2011, 102, 1972-1976.	1.7	9
99	Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phaseÂIII trial. Journal of Neuro-Oncology, 2011, 103, 595-602.	1.4	29
100	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1301-1308.	1.2	32
101	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 2011, 117, 501-509.	2.0	126
102	Clinical dissection of multicentric Castleman disease. Leukemia and Lymphoma, 2011, 52, 1517-1522.	0.6	36
103	VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. Diagnostic Molecular Pathology, 2011, 20, 143-147.	2.1	4
104	EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. Japanese Journal of Clinical Oncology, 2011, 41, 548-554.	0.6	10
105	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. Oncology, 2011, 80, 395-405.	0.9	48
106	Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro-Oncology, 2011, 13, 195-202.	0.6	51
107	Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study. Japanese Journal of Clinical Oncology, 2011, 41, 245-252.	0.6	5
108	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 320-325.	0.5	54

#	Article	IF	Citations
109	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer, 2010, 10, 448.	1.1	42
110	Firstâ€line therapy with doxycycline in ocular adnexal mucosaâ€associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. Cancer Science, 2010, 101, 1199-1203.	1.7	48
111	Definitive Radiotherapy With or Without Chemotherapy for T3-4N0 Squamous Cell Carcinoma of the Maxillary Sinus and Nasal Cavity. Japanese Journal of Clinical Oncology, 2010, 40, 542-548.	0.6	25
112	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer, 2010, 68, 427-432.	0.9	7
113	Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clinical Neurology and Neurosurgery, 2010, 112, 758-765.	0.6	144
114	Preradiation Chemotherapy with ACNU-CDDP in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis. Chemotherapy, 2009, 55, 145-154.	0.8	2
115	Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer, 2009, 9, 450.	1.1	22
116	The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer, 2009, 9, 73.	1.1	81
117	Intensityâ€modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Head and Neck, 2009, 31, 1121-1128.	0.9	30
118	Treatment outcomes and clinicopathologic characteristics of tripleâ€negative breast cancer patients who received platinumâ€containing chemotherapy. International Journal of Cancer, 2009, 124, 1457-1462.	2.3	69
119	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2009, 116, 153-160.	1.1	41
120	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology, 2009, 29, 443-449.	0.7	37
121	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer, 2009, 65, 80-84.	0.9	118
122	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer, 2009, 65, 204-207.	0.9	29
123	Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. Lung Cancer, 2009, 65, 242-246.	0.9	13
124	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncology, The, 2009, 10, 757-763.	5.1	571
125	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. Medical Oncology, 2008, 25, 447-450.	1.2	7
126	Pulmonary resection in patients with nonsmallâ€cell lung cancer treated with gammaâ€knife radiosurgery for synchronous brain metastases. Cancer, 2008, 112, 1780-1786.	2.0	24

#	Article	IF	Citations
127	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer, 2008, 8, 148.	1.1	64
128	Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer, 2008, 8, 374.	1.1	51
129	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer, 2008, 60, 401-407.	0.9	78
130	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. Lung Cancer, 2008, 61, 30-34.	0.9	89
131	Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. Lung Cancer, 2008, 62, 381-384.	0.9	20
132	Aggressiveness of Cancer-Care near the End-of-Life in Korea. Japanese Journal of Clinical Oncology, 2008, 38, 381-386.	0.6	94
133	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenetics and Genomics, 2007, 17, 313-319.	0.7	54
134	Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer, 2007, 58, 112-115.	0.9	132
135	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer, 2007, 7, 203.	1.1	126
136	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer, 2007, 7, 63.	1.1	63
137	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. Supportive Care in Cancer, 2007, 15, 631-636.	1.0	18
138	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer, 2006, 54, 201-207.	0.9	35
139	High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Nonâ€“Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy. Clinical Cancer Research, 2006, 12, 4232-4236.	3.2	38
140	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. Leukemia and Lymphoma, 2006, 47, 1253-1259.	0.6	18
141	An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1279-1285.	0.4	268
142	Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. International Journal of Hematology, 2005, 81, 258-263.	0.7	6
143	Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. Cellular Signalling, 2005, 17, 111-119.	1.7	24
144	Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemotherapy and Pharmacology, 2005, 56, 10-14.	1.1	40

#	Article	IF	Citations
145	Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 214-217.	0.6	6
146	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biology of Blood and Marrow Transplantation, 2005, 11, 122-128.	2.0	35
147	Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4383-4388.	3.2	74
148	l-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. International Journal of Biochemistry and Cell Biology, 2004, 36, 2180-2195.	1.2	82
149	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 477-480.	0.6	41
150	A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer, 2003, 42, 227-235.	0.9	20
151	Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer. Japanese Journal of Clinical Oncology, 2003, 33, 620-625.	0.6	3
152	A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Nonâ€“Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 238-243.	0.6	45